Alternative medicine manufacturer Bioxyne posted unaudited revenue of A$29.3 million for FY25, coming in $1.3 million above its guidance figure.
A strong fourth quarter drove much of the outperformance, with the company recording $9.5 million in revenue for the period — a rise of more than 200% on the same quarter the prior year and 33% above Q3 figures.
Bioxyne also reported positive cash flow of $1.5 million in the three months to June, bringing the full-year cash flow total to $6.2 million.
The bulk of revenue came from its manufacturing arm, Breathe Life Sciences, which operates a Brisbane-based facility producing medicinal cannabis, MDMA and psilocybin.
Chief executive Sam Watson said the company is well positioned to achieve further growth in FY26, supported by ongoing expansion across Australia and increasing activity in the UK and European markets, with Germany a particular focus.
Last month, Bioxyne entered Europe's largest cannabis market by signing a $5.6 million manufacture and supply agreement with Germany-based supplier Farmakem and distributor Adrex Pharmaceuticals.
The deal will "underpin growth going into FY26," Watson said.
"The agreement with Farmakem and Adrex will add significant strength to our EU/UK operations," he added. "Initial supply will be from Australia pending the establishment of manufacturing operations in the EU/UK which is at an early stage.
"We anticipate several further additional contracts to be entered into within the region as we continue to scale up operations throughout Europe and the UK."
Watson said additional contracts currently under negotiation in Australia and internationally would also contribute to revenue growth going forward.
The company held $7.6 million in available cash at the close of June.